The sequences of the bla TEM genes encoding TEM-92 in Proteus mirabilis and Providencia stuartii isolates were determined and were found to be identical. Except for positions 218 (Lys-6) and 512 (Lys-104), the nucleotide sequence of bla TEM-92 was identical to that of bla TEM-20 , including the sequence of the promoter region harboring a 135-bp deletion combined with a G-1623T substitution. The deduced amino acid sequence of TEM-92 differed from that of TEM-52 by the presence of a substitution (Gln-63Lys) in the peptide signal.
The extended-spectrum beta-lactamases (ESBLs) observed in Proteus mirabilis and rarely in Providencia stuartii are often difficult to detect. Their detection requires a modified synergy test (16) because they are usually produced at low levels (5).
We report here on two strains, P. mirabilis CF 529 and P. stuartii 1606 (Table 1) , isolated in 1998 from the urinary tracts of two patients hospitalized at Clermont-Ferrand Hospital and Pitié-Salpêtrière Hospital in Paris, France, respectively. These isolates, in particular, P. mirabilis CF 529, were noticed because of their high level of resistance to cefotaxime and the results of the synergy test, which was unequivocally positive with oxyiminocephalosporins and clavulanic acid.
MICs were determined by a dilution method on MuellerHinton agar with an inoculum of 10 4 CFU per spot (6) . Antibiotics were provided as powders by SmithKline Beecham Pharmaceuticals (amoxicillin, ticarcillin, and clavulanate), Eli Lilly, Paris, France (cephalothin, moxalactam), Roussel-Uclaf (cefotaxime, cefpirome), Glaxo-Wellcome Research and Development (ceftazidime), Bristol-Myers Squibb (aztreonam, cefepime), and Merck Sharp & Dohme (cefoxitin). Table 2 lists the MICs of aztreonam, cefoxitin, cefotaxime alone and combined with clavulanate at a fixed concentration of 2 g/ml, ceftazidime, cefepime, cefpirome, and moxalactam for the two strains producing TEM-92, P. mirabilis CF 529 and P. stuartii 1606. They were compared with those for P. mirabilis CF 39 and P. mirabilis CF 669, two strains of the same species that produce TEM-3 and TEM-66, respectively (3). These three ESBLs, TEM-92, TEM-3, and TEM-66, have the same mutations, Glu-1043Lys and Gly-2383Ser, implicated in the extension of the spectrum of activity.
P. mirabilis CF 529 and P. stuartii 1606 differed from P. mirabilis strains CF 39 (TEM-3) and CF 669 (TEM-66) in that the first two strains had higher levels of resistance to cefotaxime (MICs for CF 529 and 1606, 64 and 32 g/ml, respectively; MICs for CF 39 and CF 669, 2 and 8 g/ml, respectively). The ceftazidime MIC was 8 g/ml for all strains except P. mirabilis CF 39 (TEM-3), for which it was 0.5 g/ml.
Aztreonam MICs (Յ2 g/ml) remained low. The four strains were susceptible to moxalactam (MICs, Յ0.25 g/ml) and cefoxitin (MICs, Յ8 g/ml), unlike Klebsiella pneumoniae NEM 865 producing TEM-52 (14) . Clavulanate restored the impaired activity of cefotaxime. Analytical isoelectric focusing was performed with crude lysates from polyacrylamide gels containing ampholines with a pH range of 3.5 to 10.0, as described previously (15) . Both of the clinical strains (P. mirabilis CF 529 and P. stuartii 1606) produced a beta-lactamase with a pI of 6.0.
Several transfer experiments were tried with mutants of Escherichia coli HB 101, E. coli C600, and P. mirabilis ATCC 29906 as recipient strains. Only one transconjugant strain was obtained by mating P. mirabilis CF 529 with rifampin-resistant P. mirabilis ATCC 29906. The phenotype of resistance to aminoglycosides (kanamycin, tobramycin, and gentamicin) observed by the diffusion method was cotransferred with the ESBL phenotype.
Plasmids from clinical isolates and the transconjugant were extracted by the method of Kado and Liu and electrophoresed at 250 V for 4 h in a 0.7% agarose gel. They were blotted onto Nytran filters.
Hybridization with a TEM probe obtained by PCR with primers TEM-A (5Ј-TAAAATTCTTGAAGACG-3Ј) and TEM-B (5Ј-TTACCAATGCTTAATCA-3Ј) (3) and labeled by random priming (DNP-DNA labeling kit; Appligen Oncor, Illkirch, France) showed that the TEM gene resided on a 50-kb plasmid of P. mirabilis CF 529 and P. stuartii 1606 (data not shown). In K. pneumoniae NEM 865 (TEM-52), ␤-lactam resistance was transferred alone, without aminoglycoside resistance genes, and was located on a 13.5-kb plasmid. Great variability in plasmid size in TEM-52-producing E. coli and K. pneumoniae strains (between 71 and 100 kb) was also observed in Korea (12) . PCR amplification and DNA sequencing of the promoter and coding regions of the bla TEM-92 gene were performed as described previously (3) .
The nucleotide sequences of the two bla TEM genes from P. mirabilis CF 529 and P. stuartii 1606 were identical. Analysis of the deduced protein sequence compared to that of bla TEM-1 showed four amino acid substitutions, Gln-63Lys, Glu1043Lys, Met-1823Thr, and Gly-2383Ser. This protein sequence is identical to that of TEM-52 reported previously (12, 14) except for the substitution Gln-63Lys in the signal peptide. We suggest that the enzyme be designated TEM-92.
In Table 3 , which shows the positions known to allow discrimination of bla TEM genes (10), the sequence of bla TEM-92 is compared with those of bla TEM-52 genes reported previously (12, 14) and with that of bla (2) . bla and bla have the same promoter with a 135-bp deletion between nucleotides 22 and 158 combined with the mutation G-1623T. This combination of the deletion and the mutation resulted in a promoter sequence that contained TTGAA for the Ϫ35 region and TACAAT for the Ϫ10 region and that is thereby of closer similarity to the consensus promoter sequence, which conferred a strong promoter (2) . No deletion was observed in the promoters of bla TEM-52 genes reported previously, in which strong promoters, P4 (G-1623T) for K. pneumoniae NEM 865 (14) and Pa ϩ Pb (C-323T) (2) except at two positions, 218 and 512 (Glu-63Lys and Glu-1043Lys, respectively), and both genes belong to the bla TEM-2 -like group (4). Among ESBLs, TEM-52 was hitherto not frequent except in Korea, where it was observed in an epidemic (12) . It was first reported in a K. pneumoniae strain isolated from a girl originating from Athens, Greece (14) , and a strain was observed in France (8) . These TEM-52 and TEM-92 enzymes, which harbor the same critical substitutions involved in the extension of the beta-lactamase spectrum at positions 104, 182, and 238, differed by their geographical locations, the species implicated, the sizes of the plasmids carrying the bla TEM gene, and their nucleotide sequences. The occurrence of these enzymes could be due to a convergent evolution from different bla TEM genes (11) .
A wide variety of TEM-type ESBLs were observed in P. mirabilis. Some of them (TEM-8, TEM-10, TEM-24, TEM-26 [3] , and TEM-87) confer a ceftazidimase resistance phenotype, whereas others (TEM-3, TEM-21, TEM-66 [3] and TEM-72 [13] ) confer a cefotaximase resistance phenotype. The latest, TEM-87, has the same mutation (Gln-63Lys) in the peptide signal as TEM-92. This diversity is perhaps related to the variety of the ecological niches of this species, which is rarely implicated in nosocomial infections (7). In P. stuartii, unlike in P. mirabilis, ESBLs were rarely reported (TEM-24 in our hospital [unpublished data] and TEM-60 [9] ). That could be due to the level of expression in this species. A lower level of expression of TEM-92 was observed in P. stuartii 1606 than in P. mirabilis CF 529. For both species we could suspect the We thank Rolande Perroux, Marlène Jan, and Dominique Rubio for technical assistance. We are grateful to C. Poyart, who kindly provided K. pneumoniae NEM 865.
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